Thymoma

The immune mechanism of its occurrence is still unclear and needs to be further studied. Traditional glucocorticoid is still the first-line drug, but the new targeted drug Efgartigimod has less adverse reactions and faster onset of action, which may become a good choice, but needs to be verified by a larger sample.

Although gene amplification is rare, protein expression is more frequent, suggesting potential for targeted therapy. Detailed molecular profiling and innovative research methods are essential to further explore the therapeutic potential of HER2 in these rare cancers.

Prognosis in TETs relies primarily on histology and staging, whereas molecular and immunological biomarkers represent emerging tools for risk stratification and treatment selection. Multiparametric models integrating clinical, pathological, and molecular data may pave the way for precision oncology in TETs.

Recognition of this relationship is important for clinical management, long-term surveillance, and therapeutic decision-making in patients with thymoma. Future studies are warranted to further define the oncogenic consequences of thymic dysfunction and its implications for cancer development.

Novel therapeutic approaches are emerging, including PRMT5 inhibitors in MTAP-deficient tumors, TROP-2-directed antibody-drug conjugates (e.g., sacituzumab govitecan), and chimeric antigen receptor (CAR) T-cell therapies targeting mesothelin. Bispecific agents such as bintrafusp alfa and ivonescimab, which co-target various pathways, offer innovative strategies. Despite these advances, TC remains a challenging malignancy with no standardized treatment algorithm. Collaborative efforts across institutions will be essential to accelerate progress and improve outcomes in this rare disease.

P1, N=18, Completed, Vastra Gotaland Region | Active, not recruiting --> Completed

Tumor microenvironment in high AKT2 expression patients demonstrated immunosuppressive characteristics such as reduced γδT cells aggregation and increased Tregs infiltration.

The levels of phosphorylated-mechanistic target of rapamycin complex 1 (p-mTORC1)/mTORC1, p-v-akt murine thymoma viral oncogene homolog 1 (AKT)/AKT, and p-phosphatidylinositol-3 kinase (PI3K)/PI3K were significantly downregulated following GPR176 knockdown. GPR176 is upregulated in OS and is associated with a poor prognosis. GPR176 suppresses mitophagy to promote OS progression by facilitating mTORC1 activity via the PI3K-AKT pathway.

Systemic therapy advances include KIT/PIK3CA-targeted agents (imatinib, everolimus) showing modest efficacy, while programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors demonstrate 20-30% response rates in thymic carcinoma but are associated with a >50% risk of severe immune-related adverse events (irAEs). Platinum-based chemotherapy [cisplatin, doxorubicin, cyclophosphamide (CAP) regimen] remains standard for advanced disease...TETs management is evolving rapidly through technological and biological advances. Future progress hinges on: (I) validating artificial intelligence (AI)-driven imaging classifiers; (II) conducting randomized controlled trials (RCTs) comparing surgical approaches; (III) elucidating immunotherapy toxicity mechanisms; and (IV) developing predictive composite biomarkers integrating genomic, immunological, and clinical parameters to enable precision medicine while mitigating fatal toxicities.

Thymoma further increased the risk of both AAN-I-IFN production and severe disease. These findings suggest a crucial immunological mechanism that could guide risk stratification and targeted interventions for MG patients during viral infections, such as COVID-19.

CD5 and CD117 are the best markers for TC. While the addition of other markers (i.e., BAP1 loss, MTAP loss and CDKN2A deletion) might be useful in cases negative for CD5 and CD117, rare cases of type B3 thymoma might harbor these alterations.

Particularly among those with STAT3 mutations, the 'QGXG' motif in 15 AA sequences of TCRβ complementarity-determining regions 3 (CDR3) regions was specifically recognized. These findings suggest that a specific immunogenetic background defined by particular HLA alleles, the expansion of somewhat limited T-cell clones and STAT3-mutated T cells are involved in the pathogenesis of chronic acquired PRCA.